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Horses were immunized by inoculation with a vaccinia construct containing a full-length cDNA corresponding to the L2
gene segment of African horsesickness virus type 4 (AHSV-4). All immunized horses developed serum neutralizing antibodies
prior to challenge with virulent AHSV-4. No ELISA-reactive antibodies were present prior to challenge. A group of four
seronegative control horses died after developing clinical signs and lesions typical of the pulmonary form of African
horsesickness while the immunized horses were clinically normal. Increases in serum neutralizing and ELISA-reactive
antibody titers following challenge indicate that at least some replication of challenge virus occurred in immunized horses.
These results demonstrate that AHSV VP2 alone is sufficient to induce a protective immune response in horses and indicate
the usefulness of ELISA-reactive antibodies for differentiation of vaccinated and naturally exposed horses. q 1996 Academic
Press, Inc.
African horsesickness (AHS) is a noncontagious dis- sion to virulence by back mutation or reassortment with
wild-type virus, incomplete attenuation or inactivation,ease of horses and other solipeds caused by an arthro-
pod-borne orbivirus of the family Reoviridae. There are and owner concerns about effects of modified live vac-
cines on performance of their horses. There are two sig-currently nine known serotypes, with the most recent
outbreaks caused by African horsesickness virus (AHSV) nificant problems with both MLV and inactivated AHS
vaccines. First, both involve growth of large amounts oftypes 4 and 9 (1, 2). The disease is enzootic in sub-
Saharan Africa and severe epizootics have occurred in live virus which may require a biocontainment facility
outside enzootic areas. Second, it is difficult to serologi-the Iberian peninsula, North Africa and the Middle East
(3–5). In 1987 an outbreak was reported in Spain, with cally differentiate vaccinated from naturally infected
horses. These problems would be eliminated by the useextension to Portugal and Morocco in 1988 (5, 6). This
outbreak continued until 1990, resulted in the death of of subunit vaccines.
A critical step in developing a subunit vaccine is tonumerous horses, and required the vaccination of thou-
sands of other horses. An outbreak of AHS in the United determine which viral protein(s) are responsible for in-
ducing a protective immune response. It has been shownStates or Europe, with the native Culicoides vectors com-
petent for AHSV in both areas, would be devastating to that VP2, which is encoded by gene segment L2, bears
the major neutralizing epitopes and thus is responsiblethe horse industry (7, 8).
AHSV is a typical orbivirus with a double-layered cap- for inducing serotype-specific responses (18–20). AHSV
type 4 (AHSV-4) VP2 bears at least three distinct, highlysid containing the genomic material consisting of 10 seg-
ments of double-stranded (ds) RNA, each encoding one conformational neutralizing epitopes (T. Burrage, unpub-
lished observation). Of particular relevance to vaccineto two proteins (9). The major outer capsid and core
structural viral proteins are VP2, VP5 and VP3, VP7, re- development are experiments performed demonstrating
that neutralizing monoclonal antibodies to VP2 passivelyspectively. In addition, there are three minor structural
proteins, VP1, VP4, and VP6, associated with the core protect mice against a lethal challenge of virus, sug-
gesting that neutralizing antibodies are sufficient for pro-and four nonstructural (NS) proteins, NS1, 2, 3, and 3a
(10–12). tection (18).
To determine if VP2, presumably by induction of neu-Current vaccines for AHS include modified live virus
(MLV) and inactivated whole virus vaccines (13–17). Al- tralizing antibodies, is sufficient for protection of horses,
we used a vaccinia construct expressing a full-length L2though these vaccines are generally effective, there are
some concerns about their use, including possible rever- gene segment (AHSV-4 VP2) to immunize horses which
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were then challenged with a lethal dose of AHSV-4, a
1990 isolate from a horse in Spain (AHSV/4SP). The data
described in this paper show that AHSV VP2, expressed
in vivo, induces neutralizing antibodies and confers com-
plete protection from disease.
A recombinant vaccinia virus expressing VP2 of AHSV-
4 was constructed by cloning the full-length L2 cDNA
(encoding the VP2 protein) into the BglII site of the trans-
fer vector pSCII (21). Correct orientation of the insert was
confirmed by restriction enzyme digest and sequence
analysis. Transfection was carried out with the WR strain
of vaccinia virus. Recombinants were selected and
plaque purified three times.
All virus stocks used were propagated and assayed
on Vero cell monolayers in DMEM media with 10% fetal
FIG. 1. Temperature: Temperature was recorded both AM and PMbovine serum and antibiotics. Vaccinia viruses, parental
each day after challenge. Mean PM temperatures from each groupWR, and the construct containing AHSV type 4 L2 gene
are presented in this figure. Control horses received Vero cell lysate,
were subjected to two freeze/thaw cycles, sonicated for vaccinia-control horses received the construct parent virus (Western
1 min, and stored at 0707 until being used for vaccina- Reserve), and vaccinia-L2 received the vaccinia construct which ex-
pressed the VP2 protein of AHSV-4. All horses were challenged withtion. The challenge virus, AHSV/4SP, was isolated in
AHSV/4SP. Error bars represent the standard errors of the mean. (Nor-1990 from an infected horse in Spain (5). This plaque
mal body temperature in horses is 99–101.57F.)purified isolate propagated in Vero cells was previously
shown to cause 100% mortality in horses, consistently
inducing the pulmonary form of AHS (22, 23). Titers of cal replication of the construct. Control horses and those
receiving parental vaccinia WR strain developed feversparental vaccinia virus and the vaccinia-L2 construct
were determined by plaque titration while AHSV titers starting on day postchallenge (dpc) 2 or 3 (Fig. 1). On
dpc 4 all control and vaccinia WR strain horses werewere determined by microtitration, both on Vero cells.
The horses used in this experiment were clinically febrile and showing clinical signs typical of the pulmo-
nary form of AHS, including anorexia, depression, andnormal and seronegative for AHSV neutralizing and
ELISA antibodies (18, 24). Horses were allowed to accli- dyspnea (Fig. 1). Fevers averaging 1047F peaked approxi-
mately 24 hr prior to death when a sudden drop in tem-matize to the biocontainment facility for 2 weeks prior to
primary inoculation. Two horses received parental vac- perature was recorded in all control horses. Immediately
prior to death, serous exudation from the nares was ob-cinia WR strain while four horses received the vaccinia-
L2 construct via three intradermal inoculations of 109 served in some horses. Horses either died suddenly or
were euthanized in extremis by injection of pentobarbitalPFU at 3-week intervals. A negative control horse re-
ceived Vero lysate prepared in the same manner as the (Fatal-Plus, Vortech Pharmaceuticals, Dearborn, MI). On
postmortem examination the predominant lesion was se-vaccinia-L2 Vero lysate. All inoculations were given on
the lateral aspect of the neck. The immunized and control vere pulmonary edema, sometimes accompanied by mild
pleural effusion. Horses that received the vaccinia-L2horses were challenged 3 weeks after the last inocula-
tion by intravenous injection of 5 1 104 TCID50 of AHSV/ construct did not show any clinical signs associated with
AHS during the 21-day observation period (Fig. 1). Titers4SP. Three naive control horses from a parallel experi-
ment received an identical dose of the challenge virus of AHSV in blood correlated well with fevers in control
horses (Fig. 2). All horses that did not receive the vac-and were included for statistical purposes in analysis of
this experiment. After challenge, the horses were ob- cinia-L2 construct were viremic starting on dpc 3, with
titers of at least 104 TCID50/ml recorded prior to death.served each day for clinical manifestations of AHS. Blood
samples for virus titrations, serum neutralization, and Viremia above a limit of detection of 100.5 TCID50/ml was
not present in any of the animals that received the vac-ELISA were taken daily. To determine if VP2 was ex-
pressed in vivo prior to challenge, radioimmunoprecipita- cinia-L2 construct.
Sera obtained from horses 1 week after each inocula-tions (RIP) were performed as previously described utiliz-
ing [35S]methionine-labeled AHSV/4SP-infected Vero cell tion of the vaccinia-L2 construct did not contain signifi-
cant neutralizing titers until after the third inoculation.lysate as antigen (18). RIPs utilizing preinoculation, pre-
challenge, and postchallenge horse sera were analyzed All horses which received the vaccinia-L2 construct had
neutralizing serum antibody titers prior to challenge, al-by electrophoresis on 10% SDS–PAGE gels with autora-
diographic detection. though the titers were low (Fig. 3). Serum neutralizing
antibody titers increased after challenge in immunizedHorses that received the vaccinia-L2 construct devel-
oped small swellings at inoculation sites, suggesting lo- horses (Fig. 3). Prior to challenge there were no detect-
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FIG. 2. Viremia: Heparinized whole-blood samples were collected FIG. 4. ELISA. A single dilution ELISA was performed as previously
from all horses each day after challenge for 14 days. Presented are described, utilizing plates coated with the homologous challenge virus
the viremic titer of each horse. Viremia was quantified by microtitration (AHSV/4SP) (24). Binding of anti-AHSV antibodies was detected using
as previously described (25). Endpoints were determined by the method biotin-labeled goat anti-horse IgG (Kirkegaard and Perry Laboratories,
of Spearman and Karber (26). Control horses received Vero cell lysates, Gaithersburg MD) and avidin-alkaline phosphatase (Boehringer-Mann-
vaccinia-control horses received the construct parent virus (WR), and heim, Indianapolis, IN). The absorbance at 495 nm was determined
vaccinia-L2 received a vaccinia construct which expressed the VP2 and compared to that derived from hyperimmune horse sera to obtain
protein of AHSV-4. Limit of detection in this experiment because of the titers. No ELISA-reactive antibodies were detected in control horses
manipulations required was 0.5 (0)log10/ml. (data not shown).
able ELISA-reactive antibodies in sera from control or L2-immunized horses recognized all structural and non-
immunized horses. However, ELISA-reactive antibody ti- structural AHSV proteins by dpc 21 (Fig. 5).
ters increased in immunized horses starting on dpc 7 The results of this study, utilizing a vaccinia construct
(Fig. 4). Control and vaccinia WR strain horses died be- containing the L2 gene from AHSV-4 and a well-charac-
fore developing detectable levels of either neutralizing terized homologous challenge system, indicate that
or ELISA antibodies. Protein specificity of the antibody AHSV VP2 is sufficient to induce a protective immune
response to immunization and challenge was deter-
mined by RIP. A single band was precipitated by sera
from immunized horses prior to challenge which comi-
grates with VP2 at 116 kDa (Fig. 5). Sera from vaccinia-
FIG. 3. Serum neutralization: Assays were performed as previously
described (8). Twofold dilutions of the sera were incubated with 100
TCID50 of challenge virus (AHSV/4SP) for 1 hr at 377, 5% CO2 in 96-well
plates after which, Vero cells were added and incubated for 5–6 days. FIG. 5. Radioimmunoprecipitation of [35S]methionine-labeled AHSV
proteins by serum from a horse immunized with vaccinia-L2 and chal-Endpoints were defined by those wells in which 75% of the monolayer
remained intact. The neutralizing titers of Horses 1, 9, 14, and 23 (vac- lenged with AHSV/4SP. On the day of challenge (dpc 0) serum from
this horse recognizes only VP2 while 3 weeks postchallenge mostcinia-L2 immunized) in this study are compared to titers from horses
vaccinated with a MLV vaccine and challenged with the same isolate AHSV proteins are precipitated. Immunoprecipitates by serum from
naive (control) and hyperimmunized horses are included in the twoused in this study. The values presented for the MLV vaccinates are
geometric mean titers (n  4). right-hand lanes.
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